Show simple item record

dc.contributor.authorBorghaei, Hossein
dc.contributor.authorAlpaugh, Katherine
dc.contributor.authorHedlund, Gunnar
dc.contributor.authorForsberg, Goran
dc.contributor.authorLanger, Corey J
dc.contributor.authorRogatko, Andre
dc.contributor.authorHawkins, Robert E
dc.contributor.authorDueland Svein
dc.contributor.authorLassen, Ulrik
dc.contributor.authorCohen, Roger B
dc.date.accessioned2009-11-03T14:22:36Z
dc.date.available2009-11-03T14:22:36Z
dc.date.issued2009
dc.identifier.citationPhase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer. 2009, 27(25): 4116-4123 J Clin Oncen
dc.identifier.issn0732183X
dc.identifier.issn15277755
dc.identifier.doi10.1200/JCO.2008.20.2515
dc.identifier.urihttp://hdl.handle.net/10541/85228
dc.language.isoenen
dc.subjectAdvanced Canceren
dc.subjectNon-Small-Cell Lung Canceren
dc.subjectABR-217620en
dc.subjectDose Escalationen
dc.titlePhase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung canceren
dc.typeArticleen
dc.contributor.departmentChrisite Research Centre, Manchester, United Kingdomen
dc.identifier.journalJournal of Clinical Oncologyen


This item appears in the following Collection(s)

Show simple item record